JPWO2020097561A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020097561A5 JPWO2020097561A5 JP2021524282A JP2021524282A JPWO2020097561A5 JP WO2020097561 A5 JPWO2020097561 A5 JP WO2020097561A5 JP 2021524282 A JP2021524282 A JP 2021524282A JP 2021524282 A JP2021524282 A JP 2021524282A JP WO2020097561 A5 JPWO2020097561 A5 JP WO2020097561A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- occupied
- cdr
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 102000013498 tau Proteins Human genes 0.000 claims 8
- 108010026424 tau Proteins Proteins 0.000 claims 8
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 6
- 208000034799 Tauopathies Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 208000017004 dementia pugilistica Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002518 glial effect Effects 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 206010048327 Supranuclear palsy Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 208000018726 traumatic encephalopathy Diseases 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000033556 type C1 Niemann-Pick disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025003312A JP2025063136A (ja) | 2018-11-08 | 2025-01-09 | タウ認識抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/059895 WO2020096608A1 (en) | 2018-11-08 | 2018-11-08 | Antibodies recognizing tau |
| USPCT/US2018/059895 | 2018-11-08 | ||
| US201862758421P | 2018-11-09 | 2018-11-09 | |
| US62/758,421 | 2018-11-09 | ||
| PCT/US2019/060616 WO2020097561A1 (en) | 2018-11-08 | 2019-11-08 | Antibodies recognizing tau |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003312A Division JP2025063136A (ja) | 2018-11-08 | 2025-01-09 | タウ認識抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022506719A JP2022506719A (ja) | 2022-01-17 |
| JP2022506719A5 JP2022506719A5 (https=) | 2022-11-15 |
| JPWO2020097561A5 true JPWO2020097561A5 (https=) | 2022-11-15 |
| JP7623699B2 JP7623699B2 (ja) | 2025-01-29 |
Family
ID=70610738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524282A Active JP7623699B2 (ja) | 2018-11-08 | 2019-11-08 | タウ認識抗体 |
| JP2025003312A Pending JP2025063136A (ja) | 2018-11-08 | 2025-01-09 | タウ認識抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003312A Pending JP2025063136A (ja) | 2018-11-08 | 2025-01-09 | タウ認識抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220153821A1 (https=) |
| EP (1) | EP3877410A4 (https=) |
| JP (2) | JP7623699B2 (https=) |
| KR (1) | KR20210090184A (https=) |
| CN (2) | CN113454112B (https=) |
| AU (1) | AU2019377595A1 (https=) |
| BR (1) | BR112021008624A2 (https=) |
| CL (1) | CL2021001158A1 (https=) |
| CO (1) | CO2021007370A2 (https=) |
| CU (1) | CU24781B1 (https=) |
| IL (1) | IL283049A (https=) |
| JO (1) | JOP20210098A1 (https=) |
| MX (1) | MX2021005411A (https=) |
| PE (1) | PE20211777A1 (https=) |
| PH (1) | PH12021551048A1 (https=) |
| SG (1) | SG11202104549TA (https=) |
| UA (1) | UA129124C2 (https=) |
| WO (1) | WO2020097561A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| SG11202104549TA (en) * | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CA3266790A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | TAU PROTEIN BINDING COMPOUNDS |
| CN115724967A (zh) * | 2022-09-21 | 2023-03-03 | 天津鸿宇泰生物科技有限公司 | 一种识别Tau蛋白N端区域的单克隆抗体及其应用 |
| CN116925217B (zh) * | 2023-09-14 | 2024-03-08 | 北京凯祥弘康生物科技有限公司 | 针对Tau蛋白的抗体 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| WO2000046750A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| CA2471849A1 (en) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| KR101149777B1 (ko) | 2002-11-29 | 2012-06-11 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 신규한 네오마이신 포스포트랜스퍼라제 유전자 및 고생산성 재조합 세포의 선별 방법 |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| WO2006051065A2 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| EP2522729A1 (en) | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| BR112013008765B8 (pt) * | 2010-10-11 | 2023-05-02 | Biogen Idec Int Neuroscience Gmbh | Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa |
| ES2656442T3 (es) * | 2011-09-19 | 2018-02-27 | Axon Neuroscience Se | Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer |
| JP6293731B2 (ja) * | 2012-04-05 | 2018-03-14 | エーシー イミューン エス．エー． | ヒト化タウ抗体 |
| PT2935326T (pt) * | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Anticorpos anti-tau humanos |
| SI3221349T1 (sl) * | 2014-11-19 | 2021-02-26 | Axon Neuroscience Se | Humanizirano tau protitelo pri alzheimerjevi bolezni |
| EP4465050A3 (en) * | 2015-06-05 | 2025-06-11 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| US10639383B2 (en) | 2015-11-23 | 2020-05-05 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
| CA3022515A1 (en) * | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CA3030754C (en) * | 2016-07-20 | 2022-04-26 | Anahit Ghochikyan | Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| SG11202104549TA (en) * | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| EP3935083A4 (en) * | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
-
2019
- 2019-11-08 SG SG11202104549TA patent/SG11202104549TA/en unknown
- 2019-11-08 CN CN201980073684.9A patent/CN113454112B/zh active Active
- 2019-11-08 CN CN202411549401.2A patent/CN119409813A/zh active Pending
- 2019-11-08 CU CU2021000039A patent/CU24781B1/es unknown
- 2019-11-08 US US17/291,986 patent/US20220153821A1/en active Pending
- 2019-11-08 BR BR112021008624-2A patent/BR112021008624A2/pt unknown
- 2019-11-08 MX MX2021005411A patent/MX2021005411A/es unknown
- 2019-11-08 PE PE2021000683A patent/PE20211777A1/es unknown
- 2019-11-08 UA UAA202103099A patent/UA129124C2/uk unknown
- 2019-11-08 WO PCT/US2019/060616 patent/WO2020097561A1/en not_active Ceased
- 2019-11-08 JP JP2021524282A patent/JP7623699B2/ja active Active
- 2019-11-08 EP EP19881978.1A patent/EP3877410A4/en active Pending
- 2019-11-08 KR KR1020217014397A patent/KR20210090184A/ko active Pending
- 2019-11-08 AU AU2019377595A patent/AU2019377595A1/en active Pending
-
2021
- 2021-05-03 CL CL2021001158A patent/CL2021001158A1/es unknown
- 2021-05-04 JO JOP/2021/0098A patent/JOP20210098A1/ar unknown
- 2021-05-06 PH PH12021551048A patent/PH12021551048A1/en unknown
- 2021-05-09 IL IL283049A patent/IL283049A/en unknown
- 2021-06-04 CO CONC2021/0007370A patent/CO2021007370A2/es unknown
-
2025
- 2025-01-09 JP JP2025003312A patent/JP2025063136A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7166457B2 (ja) | ｃ－Ｋｉｔに対するヒト化抗体 | |
| IL262726B1 (en) | Antibodies recognizing tau | |
| JP2025029046A5 (https=) | ||
| JP6993992B2 (ja) | 抗ｐｄ－１抗体、その産生方法及びその使用方法 | |
| RU2570633C2 (ru) | Три- или тетраспецифические антитела | |
| CA3222764A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| JP2020078319A (ja) | Ｃｄ２６９（ｂｃｍａ）に対する抗体 | |
| JP2019525724A5 (https=) | ||
| JP2018510617A5 (https=) | ||
| JP2016512551A5 (https=) | ||
| JP2010532764A5 (https=) | ||
| HRP20120759T1 (hr) | Bispecifična veziva specifična između vrsta | |
| JP6666257B2 (ja) | プロアポトーシス活性を有するｇｄ２−ｏ−アセチル化ガングリオシドに対する抗体 | |
| JP2021094022A5 (https=) | ||
| JP2012525829A5 (https=) | ||
| JP2018509889A5 (https=) | ||
| US20220306760A1 (en) | Igm glycovariants | |
| JPWO2020097561A5 (https=) | ||
| JP2022501065A5 (https=) | ||
| JP2023139025A (ja) | 二重特異性抗原結合コンストラクト | |
| AU2023295644A1 (en) | Bispecific antibody containing anti-cldn18.2 antibody, and pharmaceutical composition and use thereof | |
| CN114025797A (zh) | 抗Gal9免疫抑制性结合分子 | |
| JPWO2020180819A5 (https=) | ||
| EP3904392A1 (en) | Bivalent bispecific antibody and prepartion method thereof, coding gene, host cell and composition | |
| CN121554593A (zh) | 靶向g蛋白偶联受体的双特异性抗体 |